

Research Article

Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine

Chumeng Chen,¹ Mohanad Aldarouish ,^{2,3,4} Qilong Li,^{2,3} Xiangzhen Liu,^{2,3} Feng Han,⁴ Hui Liu,⁴ and Qijun Qian ^{1,2,3,4}

¹Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China

²Shanghai Cell Therapy Research Institute, Shanghai 201805, China

³Shanghai Research and Development Center, Shanghai Cell Therapy Group, Shanghai 201805, China

⁴Immune Cell Division, Shanghai Cell Therapy Group, Shanghai 201805, China

Correspondence should be addressed to Mohanad Aldarouish; imm_moh@yahoo.com and Qijun Qian; qian@shcell.org

Received 21 December 2019; Revised 3 March 2020; Accepted 11 March 2020; Published 4 April 2020

Academic Editor: Pedro A. Reche

Copyright © 2020 Chumeng Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The success of peptide-based dendritic cell (DC) cancer vaccines mainly depends on the utilized peptides and selection of an appropriate adjuvant. Herein, we aimed to evoke a broad immune response against multiple epitopes concurrently in the presence of immunoadjuvant. Three synthetic HLA-A*0201-restricted peptides were separately linked with HMGB1-derived peptide (SAFFLFCSE, denoted as HB₁₀₀₋₁₀₈) as immunoadjuvant via double arginine (RR) linker and loaded onto human monocyte-derived DCs. Peptide uptake was detected by immunofluorescence microscopy and flow cytometry. The maturation and activation status of pulsed DCs were monitored by detection of the expression of specific markers and released cytokines. The ability of peptide-pulsed DCs to activate allogeneic T cells has been assessed by a degranulation assay and detection of secreted cytokines. The lytic activity of effector T cells against cancer cells in vitro was analyzed by a lactate dehydrogenase (LDH) assay. Results revealed that DCs efficiently take up peptides+HB₁₀₀₋₁₀₈ and expressed higher levels of surface markers (HLA-ABC, HLA-DR, CD80, CD86, CD83, CD40, and CCR7) and proinflammatory cytokines (IL-6, IFN- γ , TNF- α , and IL-12) than control DCs, free peptide-pulsed DCs, and free HB₁₀₀₋₁₀₈-pulsed DC groups. Moreover, peptides+HB₁₀₀₋₁₀₈/pulsed DCs were capable of activating allogeneic T cells and enhance their lytic activity against a pancreatic cancer cell line (PANC-1) in vitro. These findings suggest that antigenic peptides covalently linked with HB₁₀₀₋₁₀₈/pulsed DCs could be a promising strategy to improve the current DC-based cancer vaccines.

1. Introduction

The unique characteristics of dendritic cells (DCs) as the most potent antigen-presenting cells (APCs) lead them to be considered as a promising tool for cancer immunotherapy [1]. In the last few years, there has been a growing interest in peptide-, RNA-, and DNA-based DC vaccines as an effective approach for cancer immunotherapy due to its promising results in achieving significance and durable treatment responses with mild adverse events [2, 3]. Peptide-based vaccines provide several advantages in comparison to other

types of cancer vaccines. They are easily synthesized, stable in many storage conditions, and safe, and they could enhance an effective CD4 and CD8 immune response. However, the success of the peptide-based vaccine strategy mainly depends on the utilized peptides and selection of an appropriate adjuvant [4].

High mobility group box 1 (HMGB1) is highly conserved protein in mammals that translocates to the nucleus to regulate the gene expression and released during cell injury and inflammation [5]. HMGB1 is composed of two DNA-binding motifs, box A and box B, in addition to C tail

[6]. It has been found that HP91, a short peptide corresponding to amino acids 91–108 in the B box, has the ability to enhance the maturation and activation of DCs, induce the secretion of proinflammatory cytokines such as IL-6 and IL-12, and trigger the polarization of Th1 cells [7–9]. Saenz and his group demonstrated that HP91 could function as adjuvant *in vivo* through potentiating cellular and humoral immune responses [10]. Further studies showed that the region of HP91 which is responsible for its immunostimulatory function is located in the C-terminal, a peptide corresponding to amino acids 100–108 of HMGB1 [10, 11]. In this study, we denoted this short peptide as HB₁₀₀₋₁₀₈.

It is well known that no single antigenic peptide might be adequate to achieve an efficient antitumor immune response. Thus, multiple epitopes are required to elicit a broad immune response [12]. Consequently, combining multiple tumor-associated antigens (TAA) could be a preferable strategy to elicit strong antitumor immunity.

A large number of studies confirmed that the following tumor-associated antigens, survivin, human epidermal growth factor receptor 2 (Her2), and carcinoembryonic antigen (CEA), are overexpressed in a variety of tumors, by which survivin is overexpressed in the lung, breast, pancreatic, and melanoma [13–16]; Her2 is overexpressed in the breast, stomach, ovary, uterine serous endometrial carcinoma, colon, pancreatic, bladder, lung, uterine cervix, head and neck, and esophagus cancer [17, 18]; and CEA is overexpressed in gastric, colorectal, breast, ovarian, lung, and pancreatic cancer [19].

In this study, human monocyte-derived DCs (moDCs) were pulsed with three antigenic peptides, survivin, Her2, and CEA, which are covalently linked with HB₁₀₀₋₁₀₈ via protease-sensitive linker (double arginine (RR)). Results revealed that peptides covalently linked with HB₁₀₀₋₁₀₈ (denoted as peptides+HB₁₀₀₋₁₀₈) were efficiently taken up by immature DCs and significantly induced their maturation and activation compared with free peptides without HB₁₀₀₋₁₀₈ (denoted as peptides-HB₁₀₀₋₁₀₈). Moreover, peptides+HB₁₀₀₋₁₀₈/pulsed DCs greatly induced the activation and lytic activity of allogeneic T cells by which they exhibited a potent cytotoxicity against tumor cells *in vitro*.

2. Materials and Methods

2.1. DC Generation. Monocyte-derived DCs were generated from peripheral blood monocyte (PBMC) by standard Ficoll density centrifugation (GE Healthcare, Uppsala, Sweden) to isolate PBMCs from patient leukapheresis samples. PBMCs were plated in serum-free AIM-V media (Life Technologies, Grand Island, NY) and allowed to adhere to 0.22 μ m filter-capped culture flasks (TPP, Germany). After 2 hours, the nonadherent cells were removed, and adherent monocytes were subsequently cultured for 6 days in AIM-V containing 50 ng/ml rhIL-4 (R&D Systems, Minneapolis, MN) and 100 ng/ml rhGM-CSF (Sanofi, Bridgewater, NJ). On day 3, half of the medium was replaced with fresh medium containing GM-CSF and IL-4. In some experiments, a maturation cocktail containing 100 IU/ml IFN- γ , 30 μ g/ml poly(I:C), and 5 μ g/ml R848 was used to mature the generated DCs.

2.2. Synthetic Peptides. The following synthetic HLA-A*0201-restricted peptides, survivin (LTLGEFLKL), Her2 (RLQETELV), CEA (YLSGANLNL), and HB₁₀₀₋₁₀₈ (SAFFLFCSE), were synthesized with purity greater than 95%. Following their synthesis, the first three peptides were linked with HB₁₀₀₋₁₀₈ via a protease-sensitive linker (double arginine (RR) residue sequence). It is expected that once DCs internalize a peptide-RR-HB₁₀₀₋₁₀₈ construct, the intracellular proteases would cleave at the RR site and separate peptide from HB₁₀₀₋₁₀₈ and thus could enhance the processing and presentation of engulfed peptides [20]. Peptides were purchased from Shanghai Top-peptide Bio Co., Ltd. (Shanghai, China). To examine their phagocytosis by DCs, peptides \pm HB₁₀₀₋₁₀₈ were labeled with FITC fluorochrome at their N-terminus. All peptides were dissolved in PBS.

2.3. Peptide Uptake Assay. Immature moDCs, generated as described above, were seeded in a 24-well plate and pulsed separately with synthetic peptides \pm HB₁₀₀₋₁₀₈-coupled FITC (40 μ g/ml for each peptide) for 1 hour at 37°C, 5% CO₂. After a triple wash with PBS, cells were examined by fluorescent microscopy and the uptake was quantified by FACS analysis. To quench the extracellular FITC signal, 50 μ g/ml of trypan blue was added to the cell suspension prior to flow cytometry analysis. Unpulsed DCs were used as the negative control. Cells that were found positive for FITC were considered as cells that had successfully engulfed peptides.

2.4. Flow Cytometry. The purity of generated DCs was assessed as CD14⁺CD11C⁺ by staining 1×10^6 cells with anti-CD11C-APC and anti-CD14-FITC (BD Biosciences, San Diego, CA, USA).

Immature moDCs were resuspended to 1×10^6 cells/ml and loaded with peptides \pm HB₁₀₀₋₁₀₈ (40 μ g/ml for each peptide) or 40 μ g/ml of free HB₁₀₀₋₁₀₈ at 37°C, 5% CO₂. After one hour, pulsed DCs were washed and cultured overnight. The following monoclonal antibodies (mAbs) were used to characterize the maturation and activation status of DCs: anti-HLA-ABC-PE, anti-HLA-DR-PE/Cy7, anti-CD80-PE, anti-CD86-APC, anti-CD83-APC, anti-CD40-Alexa Fluor 700, and anti-CCR7-PE/Cy7 (BioLegend, San Diego, CA, USA). Isotype-matched fluorescent antibodies were used as negative controls. Cells were incubated with antibodies at 4°C for 30 minutes. After washing, samples were detected by a FACSCalibur analyzer (BD Biosciences, San Jose, CA, USA). The data were analyzed by FlowJo software (TreeStar).

2.5. Enzyme-Linked Immunosorbent Assay (ELISA). Immature moDCs were resuspended to 1×10^6 cells/ml and loaded with peptides \pm HB₁₀₀₋₁₀₈ (40 μ g/ml for each peptide) or only 40 μ g/ml of free HB₁₀₀₋₁₀₈ at 37°C, 5% CO₂. After one hour, pulsed DCs were washed and cultured for 48 hours. The secreted IL-12 was detected by a IL-12 ELISA kit (Sino Biological, China) according to the manufacturer's protocol. The optical density (OD) of samples was assessed at 550 nm using a microtiter plate spectrophotometer (Beckman Coulter detection platform, USA).

2.6. Degranulation Assay and Cytokine Detection. Peptides \pm HB₁₀₀₋₁₀₈/pulsed DCs were cultured in the presence of a

maturation cocktail (100 IU/ml IFN- γ , 30 μ g/ml poly(I:C), and 5 μ g/ml R848) for 24 hours. Cells were washed extensively and seeded with responder allogeneic T cells at a DC : T cell ratio of 1 : 10 for 18 hours. Supernatants were collected at the end of culture, and cytokine production was detected using a cytometric bead array (CBA) kit (BD Biosciences), following the manufacturer's instructions.

For the CD107a degranulation assay, allogeneic T cells were stimulated with empty DCs or peptides \pm HB₁₀₀₋₁₀₈/pulsed DCs (at a DC : T cell ratio of 1 : 10) in the presence of GolgiStop (monensin, BD) and anti-CD107a-APC mAb (BD Pharmingen). After incubation for 12 hours at 37°C, cells were collected and stained with anti-CD8-PE mAb (BD Pharmingen) and analyzed by flow cytometry.

2.7. Cancer Cells. The human pancreatic cancer PANC-1 cell line (ATCC® CRL-1469™) was cultured in DMEM supplemented with 10% FBS and penicillin/streptomycin at 37°C in a humidified 5% CO₂ atmosphere.

2.8. Cytotoxicity Assays. Peptides \pm HB₁₀₀₋₁₀₈-pulsed DCs were matured in the presence of a maturation cocktail, followed by coculturing with allogeneic T cells at DC : T cell ratios of 1 : 10 for 24 hours. Then, T cells were collected as effector cells, and Panc-1 cells were used as the target cells. Effector cells included the negative control group (T cells without preculturing with DCs), empty DC group (T cells stimulated with nonpulsed DCs), peptides-HB₁₀₀₋₁₀₈ group (T cells stimulated with free peptides/pulsed DCs), and peptides+HB₁₀₀₋₁₀₈ group (T cells stimulated with peptides covalently linked with HB₁₀₀₋₁₀₈/pulsed DCs). Effector cells and target cells (PANC-1 cancer cell line) were incubated at ratios of 5 : 1 for 4 h at 37°C in 96-well plates. The activity of T cells against the target tumor cells was measured by an LDH cytotoxicity assay kit (Beyotime, China) following the manufacturer's instructions. The cytotoxicity of the T cells was calculated as a percentage of specific lysis using the following formula: %specific lysis = (effector/target release – spontaneous release)/(maximal release – spontaneous release) \times 100%. Data are presented as the means \pm standard deviation.

2.9. Statistical Analysis. Statistical analyses were carried out using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). The mean \pm SD was determined for each treatment group in the individual experiments. Differences among groups were analyzed using Student's *t*-test, and *P* < 0.05 was considered statistically significant.

3. Results

3.1. Immature moDCs Efficiently Take Up Peptides Covalently Linked with HB₁₀₀₋₁₀₈. In this study, three antigenic synthetic peptides (survivin, Her2, and CEA) were covalently linked with HB₁₀₀₋₁₀₈ (as immunoadjuvant) via double arginine (RR) residues as a protease-sensitive linker (Figure 1(a)). To detect whether the covalent linking of synthetic peptides with HB₁₀₀₋₁₀₈ via RR linker could accelerate their acquisition by DCs, cells were incubated with survivin \pm HB₁₀₀₋₁₀₈, Her2 \pm HB₁₀₀₋₁₀₈, or CEA \pm HB₁₀₀₋₁₀₈ in culture medium for

1 hour at 37°C. All peptides were conjugated with FITC. Flow cytometry results showed that DCs more efficiently take up peptides covalently linked with HB₁₀₀₋₁₀₈ than single free peptides (Figure 1(b)). The high efficiency of DCs to engulf peptides+HB₁₀₀₋₁₀₈ was also confirmed by immunofluorescence microscopy (Figure 1(c)). These findings indicate that HB₁₀₀₋₁₀₈ could play an important role in the acceleration of peptide phagocytosis by immature DCs.

3.2. Maturation and Activation of DCs Were Induced by Peptides Covalently Linked with HB₁₀₀₋₁₀₈. To determine the optimum concentration of peptides covalently linked with HB₁₀₀₋₁₀₈ that promote the highest level of DC maturation and activation, cells were loaded with different concentrations of peptides+HB₁₀₀₋₁₀₈ (0, 20, 40, and 60 μ g/ml for each peptide) for 1 hour. Then, cells were collected, washed, and cultured overnight followed by detection of surface markers by flow cytometry. Data revealed that peptides+HB₁₀₀₋₁₀₈ induced the expression levels of HLA-ABC, HLA-DR, CD80, CD83, CD40, and CCR7 in a dose-dependent manner without a significant difference between 40 and 60 μ g/ml (Supplementary Figure 1). Based on these findings, 40 μ g/ml of peptides+HB₁₀₀₋₁₀₈ was used as a preferable concentration in the next experiments.

To detect whether peptides+HB₁₀₀₋₁₀₈ could induce the maturation and activation of DCs, immature DCs were divided into four groups: group (1) cells left untreated; group (2) cells incubated with free peptides: survivin, Her2, and CEA; group (3) cells incubated with survivin+HB₁₀₀₋₁₀₈, Her2+HB₁₀₀₋₁₀₈, and CEA+HB₁₀₀₋₁₀₈; and group (4) cells incubated with free HB₁₀₀₋₁₀₈. After 1 hour, cells were collected, washed, and cultured overnight followed by detection of surface markers by flow cytometry. Results showed that peptides+HB₁₀₀₋₁₀₈/pulsed DCs exhibited remarkably increased expression of HLA-ABC, HLA-DR, CD80, CD86, CD83, CD40, and CCR7 compared to the other three groups. Importantly, free HB₁₀₀₋₁₀₈ failed to upregulate the expression of those markers on pulsed DCs (except HLA-DR and CD86) compared with the control and peptides-HB₁₀₀₋₁₀₈/pulsed DC groups (Figure 2). These data suggest that coupling of antigenic peptides with HB₁₀₀₋₁₀₈ could serve as an efficient strategy to enhance the maturation and activation of DCs.

3.3. Peptides Covalently Linked with HB₁₀₀₋₁₀₈/Pulsed DCs Secreted Abundant Levels of Proinflammatory Cytokines. To investigate the ability of peptides covalently linked with HB₁₀₀₋₁₀₈ to enhance the secretion of proinflammatory cytokines by DCs, cells were divided into four groups and treated as mentioned in the previous section. After 1 hour of incubation, cells were collected, washed, and cultured for 48 hours to detect IL-12 by ELISA and for 24 hours to detect other cytokines. Supernatants were collected, and the level of IL-12 was detected by a CBA kit using flow cytometry. Data revealed that peptides+HB₁₀₀₋₁₀₈/pulsed DCs secreted abundant levels of IL-6 (Figure 3(a)), IFN- γ (Figure 3(b)), TNF- α (Figure 3(c)), and IL-12 (Figure 3(d)) compared to the other three groups. Consistent with the results of surface markers, the levels of those cytokines were comparable between the




FIGURE 1: Immature DCs efficiently phagocytized antigenic peptides that are covalently linked with HB₁₀₀₋₁₀₈. (a) A schematic diagram illustrates the synthetic peptides used in this study. Three HLA-A*0201-restricted peptides (survivin, Her2, and CEA) were covalently linked with HB₁₀₀₋₁₀₈ via double arginine (RR) residues as a protease-sensitive linker. (b) Immature moDCs were pulsed with 40 $\mu\text{g}/\text{ml}$ of FITC fluorochrome-conjugated peptides \pm HB₁₀₀₋₁₀₈ for 1 hour at 37°C. After a triple wash with PBS, the uptake was quantified by FACS analysis. To quench the extracellular FITC signal, 50 $\mu\text{g}/\text{ml}$ of trypan blue was added to the cell suspension prior to flow cytometry analysis. Unpulsed DCs were used as the negative control. (c) Immunofluorescence microscopy images showing the uptake of FITC-peptides+HB₁₀₀₋₁₀₈ by immature moDCs.

control DCs, peptides-HB₁₀₀₋₁₀₈, and HB₁₀₀₋₁₀₈ groups. These results demonstrate that peptides+HB₁₀₀₋₁₀₈ have a considerable potential to promote DCs to secrete proinflammatory cytokines, by which they are important in skewing of T cell responses.

3.4. Peptides Linked with HB₁₀₀₋₁₀₈/Pulsed DCs Elicited Allogeneic T Cells to Produce Several Cytokines and Induced the Lytic Activity of CD8⁺ T Cells. To investigate the lytic activity of CD8⁺ T cells, allogeneic T cells were cocultured with empty DCs or peptides \pm HB₁₀₀₋₁₀₈/pulsed DCs for 12 hours in the presence of anti-CD107a-APC mAb; then, cells were stained with anti-CD8-PE mAb and analyzed by flow cytometry. As shown in Figure 4(a), only peptides+HB₁₀₀₋₁₀₈/pulsed DCs were able to induce a robust degranulation

of CD8⁺ T cells, as identified by the expression of surface marker CD107a, indicating that those T cells could secrete cytotoxic effector molecules upon encountering DC-loaded peptides+HB₁₀₀₋₁₀₈, whereas empty DCs and DC-loaded peptides-HB₁₀₀₋₁₀₈ failed to enhance the degranulation of CD8⁺ T cells.

To evaluate the effect of DC-loaded peptides on the cytokine secretion by T lymphocytes, allogeneic T cells were cultured alone as a negative control (group 1) or cocultured with empty DCs (group 2), peptides-HB₁₀₀₋₁₀₈/pulsed DCs (group 3), or peptides+HB₁₀₀₋₁₀₈/pulsed DCs (group 4) at DC : T cell ratios of 1 : 10. 18 hours later, secreted cytokines were detected in the supernatant by the CBA kit. Data showed that the levels of secreted IL-4, IL-6, TNF- α , and IFN- γ in group 4 (peptides+HB₁₀₀₋₁₀₈/pulsed DCs/T cells) were




FIGURE 2: Peptides+HB₁₀₀₋₁₀₈ enhanced the maturation and activation of immature DCs. Immature moDCs were left untreated or pulsed with peptides±HB₁₀₀₋₁₀₈ or free HB₁₀₀₋₁₀₈ (each with 40 μg/ml) for 1 hour at 37°C. Then, cells were washed and cultured overnight. The expression of HLA-ABC, HLA-DR, CD80, CD86, CD83, CD40, and CCR7 was measured by flow cytometry. Results represent the mean ± SEM of three independent experiments.

significantly higher than those of the other three groups. Importantly, the levels of secreted IL-10 in group 4 were obviously lower than those in group 2 (empty DCs/T cells) and group 3 (peptides-HB₁₀₀₋₁₀₈/pulsed DCs/T cells) (Figure 4(b)). Collectively, these results suggest that peptides covalently linked with HB₁₀₀₋₁₀₈/pulsed DCs are potent to promote the lytic activity of T cells, as well as enhance the secretion of type 1 and type 2 cytokines and diminish the secretion of the inhibitory cytokine IL-10.

3.5. Peptides Linked with HB₁₀₀₋₁₀₈/Pulsed DCs Induced the Cytolytic Activity of T Cells against PANC-1 Cell Line In Vitro. It has been documented that pancreatic tumor cells expressed high levels of survivin, Her2, and CEA antigenic peptides [21]. To test whether the peptides±HB₁₀₀₋₁₀₈/pulsed

DCs could induce the cytolytic activity of T cells against tumor cells in vitro, allogeneic T cells were firstly cocultured with empty DCs (group 2), peptides-HB₁₀₀₋₁₀₈/pulsed DCs (group 3), or peptides+HB₁₀₀₋₁₀₈/pulsed DCs (group 4). Untreated T cells served as the negative control (group 1). After 24 hours, T cells were collected as effector cells and cocultured with PANC-1 cancer cells as target cells at a ratio of 5 : 1 (*E* : *T*). The activity of T cells against the target tumor cells was measured by the LDH cytotoxicity assays kit. As demonstrated in Figure 5, the percentage of tumor lysis in the peptides/HB₁₀₀₋₁₀₈ group was higher than that in the negative control and empty DC groups. More importantly, T cells in the peptides+HB₁₀₀₋₁₀₈ group significantly induced the lysis of tumor cells in comparison with the other three groups, indicating that peptides+HB₁₀₀₋₁₀₈/pulsed DCs could




FIGURE 3: Peptides+HB₁₀₀₋₁₀₈/pulsed DCs secreted abundant levels of proinflammatory cytokines. Immature moDCs were left untreated or pulsed with peptides±HB₁₀₀₋₁₀₈ or free HB₁₀₀₋₁₀₈ (each with 40 μ g/ml) for 1 hour at 37°C. Then, cells were washed and cultured for 24 hours, followed by detection of the secreted IL-6 (a), IFN- γ (b), and TNF- α (c) in the culture media by a cytometric bead array (CBA) kit. (d) IL-12 was detected by ELISA after 48 hours. Results represent the mean \pm SEM of three independent experiments.


stimulate high cytolytic activity of the T cells against PANC-1 *in vitro*.

4. Discussion


Immunotherapy based on peptides possesses numerous advantages including easy synthesis, low molecular weight, low toxicity, and the specific targeting of cancer cells. However, peptide-based anti-cancer vaccines encountered several limitations in the clinical setting due to several reasons including the following: (1) there is lack of CD4⁺ T cell help, (2) peptides are prone to degradation, (3) they may induce tolerance, (4) they induce low magnitude or transient

immune response, and (5) there is dysfunction of DCs upon cancer [4, 22].

In the recent years, there has been a growing interest in cancer DC-based vaccines due to their promising results in achieving meaningful treatment responses with safety profile [23]. It has been documented that compared with synthetic short peptides (SSPs), the synthetic long peptides (SLPs) are efficiently processed and crosspresented by DCs *in vivo*, resulting in the priming of both CD4⁺ and CD8⁺ T cell responses [24, 25]. Several studies indicated that the direct vaccination with short peptides may lead to tolerance and anergy and promote the growth of tumor cells [26, 27]. In contrast, *ex vivo*-differentiated DCs loaded with short peptides could elicit potent antitumor immune response



(a)



(b)

FIGURE 4: Peptides+HB₁₀₀₋₁₀₈/pulsed DCs induced the degranulation of CD8⁺ T cells and enhanced allogeneic T cells to secrete inflammatory cytokines. Immature moDCs were left untreated or pulsed with peptides±HB₁₀₀₋₁₀₈ (each with 40 μg/ml). Cells were washed and matured in the presence of a maturation cocktail for 24 hours. (a) Allogeneic T cells were stimulated with empty DCs or peptides±HB₁₀₀₋₁₀₈/pulsed DCs at T : DC cell ratio of 5 : 1 in the presence of GolgiStop and anti-CD107a-APC mAb. After incubation for 12 hours at 37°C, cells were collected and stained with anti-CD8-PE mAb and analyzed by flow cytometry. (b) Empty DCs or peptides±HB₁₀₀₋₁₀₈/pulsed DCs were cocultured with responder allogeneic T cells at a DC : T cell ratio of 1 : 5 for 18 hours. Supernatants were collected at the end of culture, and cytokine production was detected using a cytometric bead array (CBA) kit. Results represent the mean ± SEM of three independent experiments.




FIGURE 5: T cells stimulated by peptides+HB₁₀₀₋₁₀₈/pulsed DCs exert considerable lysis of the PANC-1 cell line in vitro. After stimulation with empty DCs or peptides±HB₁₀₀₋₁₀₈/pulsed DCs for 24 hours or no stimulation, allogeneic T cells were collected as the effector cells and the PANC-1 cancer cell line was used as target cells. The target cells were cocultured with the effector cells at a $T : E$ ratio of 1:5. The cytolytic activity was assessed by measurement of lactate dehydrogenase (LDH) release. This experiment has been performed in triplicate and repeated three times with similar results.

in vitro and in vivo [28, 29]. Thus, DCs appear to be a powerful carrier for the peptide-based vaccines.

As mentioned previously, the success of peptide-based vaccines mainly depends on the utilized peptides and selection of an appropriate adjuvant. Herein, it has been found that the covalent linking of adjuvant to tumor-associated antigens (TAAs) could result in the maturation and activation of DCs in vitro and induced a potent antitumor immune response in vivo compared to TAAs which they physically mixed with adjuvant [30, 31].

It is well known that Toll-like receptor (TLR) ligands have a potent activity to enhance the maturation of DCs and promote them to express proinflammatory cytokines and costimulatory molecules [32]. Later studies demonstrated that TLR ligands can efficiently increase the capacity of antigen crosspresentation in DCs [33]. HMGB1 protein has been shown to activate immune cells and induce signalling via interacting with different TLRs [34]. Thus, the addition of HMGB1 protein or its derivative peptides to the peptide-based subunit vaccines could be a promising strategy to enhance crosspresentation and crosspriming in DCs.

In this study, three antigenic synthetic peptides, which are overexpressed in several cancer types, were covalently linked with HMGB1-derived peptide (HB₁₀₀₋₁₀₈) as immunoadjuvant via double R linker and loaded into immature DCs. This design includes three main advantages: (1) long synthetic peptides, (2) the covalent linking of immunoadjuvant, and (3) RR linker, which is cleaved by the protease of DCs, and thus could facilitate and enhance the processing and presentation of loaded peptides.

It is well established that only mature DCs can costimulate and activate naïve T cells and thus requiring the recognition of peptide-MHC complexes by T cell receptor and interactions between costimulatory molecules (CD40, CD80, and CD86) on the DCs and CD28 receptors on target T cells [35]. Our data showed that peptides+HB₁₀₀₋₁₀₈ (but not peptides-HB₁₀₀₋₁₀₈ or free HB₁₀₀₋₁₀₈)/pulsed DCs exhibited high levels of several surface molecules (HLA-DR, HLA-ABC, CD83, CD80, CD86, and CD40), indicating that peptides+HB₁₀₀₋₁₀₈ could efficiently trigger the maturation and activation of immature DCs. Furthermore, peptides+HB₁₀₀₋₁₀₈/pulsed DCs expressed a high level of CCR7, which plays an important role in the migration of DCs to lymph nodes where they activate naïve T cells and elicit specific immune response [36].

It is well known that the secretion of inflammatory cytokines by DC-loaded antigen plays a crucial role in the induction of antigen-specific antitumor immune responses [37]. In this study, peptides+HB₁₀₀₋₁₀₈ (but not peptides-HB₁₀₀₋₁₀₈ or free HB₁₀₀₋₁₀₈)/pulsed DCs secreted high levels of IL-6, TNF- α , IFN- γ , and IL-12p70 and low levels of IL-10. The high level and low level of IL-12p70 and IL-10, respectively, indicate that peptides+HB₁₀₀₋₁₀₈/pulsed DCs could induce the differentiation of T cells toward Th2 phenotype [38].

These findings are consistent with previous studies indicating that the free HMGB1-derived peptide has almost no effect on the maturation and activation of DCs [31]. They are also consistent with results of studies showing that the adjuvant covalently linked to the short peptides could stimulate higher epitope recognition than the physically mixed formulation of the same molecules [39, 40]. To achieve maximum immunostimulatory effect, immunoadjuvant should be in close proximity with antigen [41]. Our data revealed that peptides+HB₁₀₀₋₁₀₈, but not free HB₁₀₀₋₁₀₈, effectively enhanced the maturation and activation of DCs after rapid phagocytosis. The potential reason is that linking epitopes with HB₁₀₀₋₁₀₈ might promote the peptide multimerization and lead to an efficient binding to the receptor of DCs via cross-linking [10]. It is important to mention that in case of direct vaccination, rather than ex vivo DC loading, peptides+HB₁₀₀₋₁₀₈ will be taken up and presented by the same APCs by which can prevent the nonspecific DC stimulation. In conclusion, HB₁₀₀₋₁₀₈ might exhibit a synergistic effect when covalently linked with antigenic peptides and thus could lead to maximizing the antitumor immune response.

Several studies indicated that the efficient DC vaccine should finally activate antigen-specific T cell responses. Thus, the ability of cytokine secretion is critical to confirm the activation status of T cells upon encountering the presented antigen by DCs [42]. In the present study, we found that the expression of IL-4, IL-6, TNF- α , and IFN- γ but not IL-10 dramatically increased after T cell interaction with peptides+HB₁₀₀₋₁₀₈/pulsed DCs, indicating that this vaccine design has the ability to activate allogeneic T cells against tumor antigen.

The ultimate goal of cancer vaccine is to drive the activated T cells toward the tumor site and selectively kill cancer cells. In this study, T cells which were activated by (survivin, Her2, and CEA)+HB₁₀₀₋₁₀₈/pulsed DCs showed a

significantly high cytolytic activity against the PANC-1 cell line in vitro. This suggests that T cell stimulated by peptides+HB₁₀₀₋₁₀₈-pulsed DCs could exert significant antigen-specific lysis on pancreatic cancer cells which express survivin, Her2, and CEA peptides.

In conclusion, our findings provide evidence that the covalently linked antigenic peptides with immunoadjuvant HB₁₀₀₋₁₀₈ are efficiently phagocytized by DCs and induce their full maturation and activation. Those activated DCs have the ability to activate allogeneic T cells and enhance their cytolytic activity against cancer cells. This work suggests a potent strategy to improve DC-based peptide immunotherapy and supports further studies to test the efficacy of this vaccine in clinical trials.

Data Availability

The relevant data used to support the findings of this study are included within the article.

Ethical Approval

This study was approved by the Medical Ethics Committee of Shanghai Cell Therapy Research Institute and carried out in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Conflicts of Interest

All authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contributions

Chumeng Chen and Mohanad Aldarouish contributed equally to this work.

Acknowledgments

This work was supported by the Natural Science Foundation of Shanghai No. 19ZR1454200.

Supplementary Materials

Supplementary Figure 1: determination of the optimum concentration of peptides+HB₁₀₀₋₁₀₈ that promote the highest level of DC maturation and activation. (*Supplementary Materials*)

References

- [1] T. A. Patente, M. P. Pinho, A. A. Oliveira, G. C. M. Evangelista, P. C. Bergami-Santos, and J. A. M. Barbuto, "Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy," *Frontiers in Immunology*, vol. 9, p. 3176, 2019.
- [2] J. Chen, H. Y. Li, D. Wang, J. J. Zhao, and X. Z. Guo, "Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro," *Journal of Gastroenterology and Hepatology*, vol. 26, no. 10, pp. 1509–1518, 2011.
- [3] B. Mastelic-Gavillet, K. Balint, C. Boudousquie, P. O. Gannon, and L. E. Kandalaft, "Personalized dendritic cell vaccines—recent breakthroughs and encouraging clinical results," *Frontiers in Immunology*, vol. 10, p. 766, 2019.
- [4] C. L. Slingluff Jr., "The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?," *The Cancer Journal*, vol. 17, no. 5, pp. 343–350, 2011.
- [5] Y. Ye, Z. Zeng, T. Jin, H. Zhang, X. Xiong, and L. Gu, "The role of high mobility group box 1 in ischemic stroke," *Frontiers in Cellular Neuroscience*, vol. 13, p. 127, 2019.
- [6] H. Yang, H. Wang, S. S. Chavan, and U. Andersson, "High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule," *Molecular Medicine*, vol. 21, Supplement 1, pp. S6–S12, 2015.
- [7] I. E. Dumitriu, P. Baruah, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini, "Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells," *European Journal of Immunology*, vol. 35, no. 7, pp. 2184–2190, 2005.
- [8] D. Messmer, H. Yang, G. Telusma et al., "High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization," *Journal of Immunology*, vol. 173, no. 1, pp. 307–313, 2004.
- [9] G. Telusma, S. Datta, I. Mihajlov et al., "Dendritic cell activating peptides induce distinct cytokine profiles," *International Immunology*, vol. 18, no. 11, pp. 1563–1573, 2006.
- [10] R. Saenz, C. S. Souza, C. T. Huang, M. Larsson, S. Esener, and D. Messmer, "HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen," *Vaccine*, vol. 28, no. 47, pp. 7556–7562, 2010.
- [11] R. Saenz, B. Messmer, D. Futalan et al., "Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization," *Molecular Immunology*, vol. 57, no. 2, pp. 191–199, 2014.
- [12] L. M. F. de Oliveira, M. G. Morale, A. A. M. Chaves et al., "Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine," *PLoS One*, vol. 10, no. 9, article e0138686, 2015.
- [13] M. Monzo, R. Rosell, E. Felip et al., "A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers," *Journal of Clinical Oncology*, vol. 17, no. 7, pp. 2100–2104, 1999.
- [14] K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa, "Expression of survivin and its relationship to loss of apoptosis in breast carcinomas," *Clinical Cancer Research*, vol. 6, no. 1, pp. 127–134, 2000.
- [15] K. Satoh, K. Kaneko, M. Hirota, A. Masamune, A. Satoh, and T. Shimosegawa, "Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer," *Pancreas*, vol. 23, no. 3, pp. 251–258, 2001.
- [16] D. Grossman, J. M. McNiff, F. Li, and D. C. Altieri, "Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma," *Journal of Investigative Dermatology*, vol. 113, no. 6, pp. 1076–1081, 1999.
- [17] N. Iqbal and N. Iqbal, "Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications," *Molecular Biology International*, vol. 2014, Article ID 852748, 9 pages, 2014.

- [18] U. Reichelt, P. Duesedau, M. C. Tsourlakis et al., "Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus," *Modern Pathology*, vol. 20, no. 1, pp. 120–129, 2007.
- [19] J. A. Hensel, V. Khattar, R. Ashton, and S. Ponnazhagan, "Recombinant AAV-CEA tumor vaccine in combination with an immune adjuvant breaks tolerance and provides protective immunity," *Molecular Therapy Oncolytics*, vol. 12, pp. 41–48, 2019.
- [20] J. T. Ulrich, W. Cieplak, N. J. Paczkowski, S. M. Taylor, and S. D. Sanderson, "Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant," *The Journal of Immunology*, vol. 164, no. 10, pp. 5492–5498, 2000.
- [21] L. F. Dodson, W. G. Hawkins, and P. Goedegebuure, "Potential targets for pancreatic cancer immunotherapeutics," *Immunotherapy*, vol. 3, no. 4, pp. 517–537, 2011.
- [22] W. Li, M. Joshi, S. Singhanian, K. Ramsey, and A. Murthy, "Peptide vaccine: progress and challenges," *Vaccine*, vol. 2, no. 3, pp. 515–536, 2014.
- [23] A. Huber, F. Dammeijer, J. G. J. V. Aerts, and H. Vroman, "Current state of dendritic cell-based immunotherapy: opportunities for in vitro antigen loading of different DC subsets?," *Frontiers in Immunology*, vol. 9, p. 2804, 2018.
- [24] R. A. Rosalia, E. D. Quakkelaar, A. Redeker et al., "Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation," *European Journal of Immunology*, vol. 43, no. 10, pp. 2554–2565, 2013.
- [25] H. Zhang, H. Hong, D. Li et al., "Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8⁺ and CD4⁺ T cells," *The Journal of Biological Chemistry*, vol. 284, no. 14, pp. 9184–9191, 2009.
- [26] R. E. Toes, R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief, "Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors," *Journal of Immunology*, vol. 156, pp. 3911–3918, 1996.
- [27] R. E. Toes, R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast, "Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 15, pp. 7855–7860, 1996.
- [28] Y. J. Choi, S. J. Park, Y. S. Park, H. S. Park, K. M. Yang, and K. Heo, "EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells," *PLoS One*, vol. 13, no. 1, article e0190638, 2018.
- [29] W. J. Lesterhuis, I. J. de Vries, G. Schreiber et al., "Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients," *Anticancer Research*, vol. 30, no. 12, pp. 5091–5097, 2010.
- [30] J. Zhao, N. Pan, F. Huang et al., "Vx3-functionalized alumina nanoparticles assisted enrichment of ubiquitinated proteins from cancer cells for enhanced cancer immunotherapy," *Bioconjugate Chemistry*, vol. 29, no. 3, pp. 786–794, 2018.
- [31] S. Dong, T. Xu, P. Wang, P. Zhao, and M. Chen, "Engineering of a self-adjuvanted iTEP-delivered CTL vaccine," *Acta Pharmacologica Sinica*, vol. 38, no. 6, pp. 914–923, 2017.
- [32] P. Blanco, A. K. Palucka, V. Pascual, and J. Banchereau, "Dendritic cells and cytokines in human inflammatory and autoimmune diseases," *Cytokine & Growth Factor Reviews*, vol. 19, no. 1, pp. 41–52, 2008.
- [33] N. I. Ho, L. G. M. Huis in 't Veld, T. K. Raaijmakers, and G. J. Adema, "Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?," *Frontiers in Immunology*, vol. 9, p. 2874, 2018.
- [34] W. L. Anggayasti, R. L. Mancera, S. Bottomley, and E. Helmerhorst, "The self-association of HMGB1 and its possible role in the binding to DNA and cell membrane receptors," *FEBS Letters*, vol. 591, no. 2, pp. 282–294, 2017.
- [35] T. Liechtenstein, I. Dufait, A. Lanna, K. Breckpot, and D. Escors, "Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy," *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry*, vol. 12, no. 3, pp. 224–235, 2012.
- [36] D. R. Saban, "The chemokine receptor CCR7 expressed by dendritic cells: a key player in corneal and ocular surface inflammation," *The Ocular Surface*, vol. 12, no. 2, pp. 87–99, 2014.
- [37] A. Gardner and B. Ruffell, "Dendritic cells and cancer immunity," *Trends in Immunology*, vol. 37, no. 12, pp. 855–865, 2016.
- [38] Y. Wang, X. Xiong, D. Wu, X. Wang, and B. Wen, "Efficient activation of T cells by human monocyte-derived dendritic cells (HMDCs) pulsed with *Coxiella burnetii* outer membrane protein Com1 but not by HspB-pulsed HMDCs," *BMC Immunology*, vol. 12, no. 1, p. 52, 2011.
- [39] P. Daftarian, R. Sharan, W. Haq et al., "Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition," *Vaccine*, vol. 23, no. 26, pp. 3453–3468, 2005.
- [40] R. L. Coffman, A. Sher, and R. A. Seder, "Vaccine adjuvants: putting innate immunity to work," *Immunity*, vol. 33, no. 4, pp. 492–503, 2010.
- [41] C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, and D. M. Klinman, "CpG DNA as a vaccine adjuvant," *Expert Review of Vaccines*, vol. 10, no. 4, pp. 499–511, 2011.
- [42] O. Millán, L. Rafael-Valdivia, E. Torrademé et al., "Intracellular IFN- γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients," *Cytokine*, vol. 61, no. 2, pp. 556–564, 2013.